Interaction Between HIV-1 Nef and Calnexin | Zendy

Ruth Hunegnaw | Zendy; Mari. Vassylyeva | Zendy; Larisa Dubrovsky | Zendy; Tatiana Pushkarsky | Zendy; Dmitri Sviridov | Zendy; Anastasia A. Anashkina | Zendy; Aykut Üren | Zendy; Beda Břicháček | Zendy; Dmitry G. Vassylyev | Zendy; Alexei A. Adzhubei | Zendy; Michael Bukrinsky | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Interaction Between HIV-1 Nef and Calnexin

Author(s) -

Ruth Hunegnaw,

Mari. Vassylyeva,

Larisa Dubrovsky,

Tatiana Pushkarsky,

Dmitri Sviridov,

Anastasia A. Anashkina,

Aykut Üren,

Beda Břicháček,

Dmitry G. Vassylyev,

Alexei A. Adzhubei,

Michael Bukrinsky

Publication year - 2016

Publication title -

arteriosclerosis thrombosis and vascular biology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.007

H-Index - 270

eISSN - 1524-4636

pISSN - 1079-5642

DOI - 10.1161/atvbaha.116.307997

Subject(s) - calnexin , human immunodeficiency virus (hiv) , computational biology , biology , virology , medicine , immunology , microbiology and biotechnology , chemistry , endoplasmic reticulum , calreticulin

HIV-infected patients are at an increased risk of developing atherosclerosis, in part because of downmodulation and functional impairment of ATP-binding cassette A1 (ABCA1) cholesterol transporter by the HIV-1 protein Nef. The mechanism of this effect involves Nef interacting with an ER chaperone calnexin and disrupting calnexin binding to ABCA1, leading to ABCA1 retention in ER, its degradation and resulting suppression of cholesterol efflux. However, molecular details of Nef-calnexin interaction remained unknown, limiting the translational impact of this finding.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research